Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000801823 | SCV000941619 | uncertain significance | Li-Fraumeni syndrome | 2023-10-23 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with serine, which is neutral and polar, at codon 242 of the TP53 protein (p.Cys242Ser). This variant is present in population databases (rs121912655, gnomAD 0.003%). This missense change has been observed in individual(s) with ovarian cancer (PMID: 30918304). ClinVar contains an entry for this variant (Variation ID: 647334). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (PMID: 12826609, 29979965, 30224644) indicates that this missense variant is expected to disrupt TP53 function. Experimental studies have shown that this missense change affects TP53 function (PMID: 9405613, 10713666, 17170001, 19681600, 20407015). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Myriad Genetics, |
RCV004028076 | SCV004931859 | likely pathogenic | Li-Fraumeni syndrome 1 | 2024-02-16 | criteria provided, single submitter | clinical testing | This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 7791795, 10713666]. This variant is expected to disrupt protein structure [Myriad internal data]. |